Related references
Note: Only part of the references are listed.The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
Juliano D. Paccez et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
Alejandro Vazquez-Martin et al.
SCIENTIFIC REPORTS (2013)
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny
Kenichi Suda et al.
CANCER AND METASTASIS REVIEWS (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer
W. Jeffrey Petty et al.
LUNG CANCER (2011)
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Kenichi Suda et al.
CLINICAL CANCER RESEARCH (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
Yi-He Ling et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
Jin Kyung Rho et al.
LUNG CANCER (2009)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
Kimio Yonesaka et al.
CLINICAL CANCER RESEARCH (2008)
EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
Toshimi Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines
Bilal Piperdi et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
In vivo antitumor activity of NVP-AEW541 -: A novel, potent, and selective inhibitor of the IGF-IR kinase
C García-Echeverría et al.
CANCER CELL (2004)
Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
T Kosaka et al.
CANCER RESEARCH (2004)
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
G Selvaggi et al.
ANNALS OF ONCOLOGY (2004)
Share Paper
